XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 93 filers reported holding XENON PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,240,418 | -11.6% | 65,586 | -0.4% | 0.00% | -33.3% |
| Q2 2023 | $2,534,340 | +21.9% | 65,827 | +13.4% | 0.00% | +50.0% |
| Q1 2023 | $2,078,326 | -3.8% | 58,070 | +6.0% | 0.00% | 0.0% |
| Q4 2022 | $2,160,330 | +37.1% | 54,789 | +25.5% | 0.00% | 0.0% |
| Q3 2022 | $1,576,000 | +56.0% | 43,653 | +31.5% | 0.00% | +100.0% |
| Q2 2022 | $1,010,000 | +9.5% | 33,184 | +10.1% | 0.00% | 0.0% |
| Q1 2022 | $922,000 | +18.7% | 30,150 | +21.1% | 0.00% | – |
| Q4 2021 | $777,000 | +171.7% | 24,904 | +33.2% | 0.00% | – |
| Q3 2021 | $286,000 | -17.3% | 18,698 | +0.4% | 0.00% | – |
| Q2 2021 | $346,000 | -19.9% | 18,617 | -22.7% | 0.00% | – |
| Q1 2021 | $432,000 | +52.7% | 24,091 | +30.4% | 0.00% | – |
| Q4 2020 | $283,000 | +87.4% | 18,478 | +35.0% | 0.00% | – |
| Q3 2020 | $151,000 | -12.2% | 13,685 | 0.0% | 0.00% | – |
| Q2 2020 | $172,000 | +20.3% | 13,685 | -5.7% | 0.00% | – |
| Q2 2019 | $143,000 | – | 14,512 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
| COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
| TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
| Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
| Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
| GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
| DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
| Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
| Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
| Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |